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PD4-2-8 Cytotoxic Chemotherapy I, Tue, 16:00 - 17:30
Advanced age is associated with lack of administration of adjuvant 
chemotherapy for completely resected stage IB-III non-small cell 
lung cancer (NSCLC)
Riely, Gregory J.; Seshan, V. E.; Azzoli, C. G.; Kris, Mark G.; Rusch, 
Valerie W.; Park, Bernard K. 
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: The number of elderly NSCLC patients continues to 
rise. Adjuvant chemotherapy for patients with resected early-stage 
NSCLC improves overall survival. However, individuals ≥70 years old 
represented just 9% of patients in the LACE meta-analysis of adjuvant 
chemotherapy trials in NSCLC (Pignon et al ASCO 2006). We sought 
to identify factors, including age, associated with administration of 
adjuvant chemotherapy.
Methods: A retrospective review of a prospective surgical database 
was performed to identify patients who underwent complete resection 
of a pathologic stage IB-III NSCLC between June 2003 and December 
2005. Patients who received preoperative therapy were excluded. 
Results: A total of 389 eligible patients were identiﬁed with a median 
age of 69 years (range 33-88). Thirty-three percent (130/389) received 
adjuvant chemotherapy. Patient characteristics are shown in the Table. 
Twenty-four percent of patients ≥70 years old received adjuvant chemo-
therapy. There was no association between receiving adjuvant chemo-
therapy and presence of medical comorbidities (CAD, CHF, HTN, any 
cardiac comorbidity, diabetes), smoking history, or type of surgical pro-
cedure (pneumonectomy, lobectomy, segmentectomy, wedge resection). 
Advancing age (p=0.002 for age ≥65, p=0.0003 for age ≥70) and pres-
ence of pathologic stage IB (p<0.0001) disease were associated with not 
receiving adjuvant chemotherapy. Controlling for stage, age was the most 
important predictor of whether patients received adjuvant chemotherapy. 
Twenty-four percent of patients ≥70 received adjuvant chemotherapy.
Conclusions: Advancing age and presence of pathologic stage IB 
disease are associated with lack of administration of adjuvant chemo-
therapy for resected NSCLC. Reasons, such as patient preference and 
clinician bias need further elucidation.
Characteristic no adjuvant chemo (n=263)
adjuvant chemo 
(n=126) p value
Stage
IB 160 (61%) 33 (26%) <0.0001
IIA 15 (6%) 18 (14%)  
IIB 35 (13%) 22 (17%)  
IIIA 33 (13%) 45 (36%)  
IIIB 20 (8%) 8 (6%)  
Median Age (range) 70 (33-87) 65 (35-88) <0.001
Cardiac Comorbidities 144 (55%) 60 (48%) 0.2
COPD 75 (29%) 23 (18%) 0.03
Diabetes 36 (14%) 9 (7%) 0.06
Kidney Disease 4 (2%) 0 (0%) 0.3
Former Smoker 241 (92%) 112 (89%) 0.5
Never Smoker 22 (8%) 14 (11%)  
Lobectomy 213 (81%) 103 (82%) 0.89
Pneumonectomy 14 (5%) 15 (12%) 0.037
Sublobar Resection 36 (14%) 8 (6%) 0.039
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Pretreatment hemoglobin level is a prognostic indicator in patients 
with non-small-cell lung cancer
Lu, Shun1 Gu, Lin-Ping2 Yu, Yong-Feng2 
1 Shanghai Chest Hospital, Jiao Tong University, Shanghai, China 2 
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Jiao Tong 
University, Shanghai, China 
Objectives: To investigate the correlation between the hemoglobin 
levels, other clinicpathologic factors, and survival time.
Methods: Anemia is deﬁned as a HB level <12.0g/dl in men and 
<11.0g/dl in women. 454 patients with non-small-cell lung cancer 
treated in the Shanghai Chest Hospital from November 2003 to March 
2005 were retrospectively analyzed. Survival analysis was evaluated by 
Kaplan-Meier and Log-Rank test. Multivariate analysis was performed 
by Cox Stepwise Regression model. The correlation of the HB level 
with survival was performed by linear regression. The HB levels were 
obtained at the initial visit to our hospital. 
Results: The median survival time for all of these patients 28.17 
months, 1-year survival rate was 73.13%. Of these, 150(33%) pa-
tients had anemia and 304(67%) patients without anemia. The median 
survival time for the patients with anemia was 20.75m; patients without 
anemia 33.14m. The 1-year survival rate was signiﬁcantly lower in 
patients with anemia than in without anemia (64%vs 77.63%, p=0.002). 
The linear regression showed a signiﬁcantly correlation between the 
HB levels with the survival time(p=0.049). In subset, the HB level of 
the patients in stage III and in male were also shown correlative with 
the survival time(p=0.03;0.01;respectively), but in stage I, II, IV or in 
female were no signiﬁcantly correlation. And the Cox Stepwise Regres-
sion analysis showed that anemia was a independent prognostic factor 
inﬂuencing survival.
Conclusion: Patients without anemia have signiﬁcantly higher survival 
rate. The HB level appears to be a signiﬁcant independent prognostic 
indicator in patients with lung cancer.
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Observing who performance status of patients undergoing 
chemotherapy for advanced non-small cell lung cancer (NSCLC)
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ACTION (Assessment of Costs and ouTcomes of chemotherapy In an 
Observational setting in patients with advanced NSCLC) is a prospec-
tive, pan-European observational study. The objective of ACTION is to 
describe advanced NSCLC treatment patterns and patient outcomes in 
routine clinical practice.
Methods: Chemonaive patients (pts) aged ≥18 yrs with stage IIIb/IV 
NSCLC were observed for 18 months from presentation for initiation 
of ﬁrst line chemotherapy (CT). All pt care, including CT given, was at 
the discretion of the pt/physician. WHO Performance Status (PS) was 
recorded at each observation: baseline, after 2 cycles of ﬁrst line CT, at 
